Another study revealed that blockade of TIM-3 can reverse the impaired phenotype of natural killer cells in patients with metastatic melanoma [16], highlighting the potential of TIM-3-targeted therapy. The gene discussed is HAVCR2; the disease is metastatic melanoma.